2019
Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM, Emery S, Molina JM, Orkin C, Gatell J, Gerstoft J, Ruxrungtham K, de Souza M, Phillips AN. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison. AIDS 2019, 33: 2337-2350. PMID: 31764099, PMCID: PMC6882545, DOI: 10.1097/qad.0000000000002359.Peer-Reviewed Original ResearchConceptsEarly antiretroviral treatmentHIV-serodifferent partnersAntiretroviral treatmentMonth 12Month 24CD4 cell countHIV-positive adultsSexual behaviorHIV infectiousnessImmediate armViral suppressionPrimary outcomeHigh prevalenceCondomless sexCell countMSMCells/Lower absolute levelsSexHeterosexual menTreatmentHeterosexualsArmAbsolute levelsPrevalence
2010
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal Of Medicine 2010, 362: 697-706. PMID: 20181971, PMCID: PMC3076221, DOI: 10.1056/nejmoa0905848.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHIVHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedPatient ComplianceRNA, ViralTuberculosisViral LoadYoung AdultConceptsSequential therapy groupHuman immunodeficiency virusAntiretroviral therapyRate of deathTuberculosis therapyHIV infectionDaily antiretroviral regimenIntegrated antiretroviral therapyIntegration of tuberculosisStandard tuberculosis therapyPositive sputum smearPrimary end pointSafety Monitoring CommitteeDiagnosis of tuberculosisAcid-fast bacilliTiming of initiationAntiretroviral regimenAdverse eventsHIV servicesImmunodeficiency virusAntiretroviral drugsSputum smearStudy groupPatientsCell count
2008
Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa
Mosam A, Hurkchand H, Cassol E, Page T, Cassol S, Bodasing U, Aboobaker J, Dawood H, Friedland G, Coovadia H. Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa. International Journal Of STD & AIDS 2008, 19: 400-405. PMID: 18595878, DOI: 10.1258/ijsa.2008.007301.Peer-Reviewed Original ResearchConceptsHIV-1-associated Kaposi's sarcomaKaposi's sarcomaCD4/CD8 cell countsHIV-1 viral loadCD8 cell countsCutaneous Kaposi's sarcomaPoor disease prognosisVirological featuresViral loadClinical parametersPatients 99Male ratioSevere diseaseDisease prognosisCell countSarcomaHIVDescriptive studyAfrican settingEqual femalePatientsOne-thirdDiseaseFemalesWomen
2004
Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8
Cassol E, Page T, Mosam A, Friedland G, Jack C, Lalloo U, Kopetka J, Patterson B, Esterhuizen T, Coovadia HM. Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8. The Journal Of Infectious Diseases 2004, 191: 324-332. PMID: 15633090, DOI: 10.1086/427337.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountDrug Therapy, CombinationFemaleHerpesvirus 8, HumanHIV InfectionsHIV-1HumansMaleMiddle AgedMycobacterium tuberculosisReverse Transcriptase InhibitorsRNA, ViralSarcoma, KaposiTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsKaposi's sarcomaHIV-1Opportunistic infectionsViral loadAfrican patientsUndetectable HIV-1 RNA levelsCell countHIV-1 RNA levelsPlasma HIV-1 levelsHuman immunodeficiency virus (HIV) infectionHIV-1 subtype CKaplan-Meier survival analysisMycobacterium tuberculosisHIV-1 levelsImmunodeficiency virus infectionProportion of patientsTarget cell availabilityHuman herpesvirus 8Immune activationTreatment regimensSubtype CTherapeutic responseTreatment outcomesVirus infectionHerpesvirus 8Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical services
2003
Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy
Schreibman T, Friedland G. Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy. Clinical Infectious Diseases 2003, 38: 257-262. PMID: 14699459, DOI: 10.1086/380792.Peer-Reviewed Original ResearchConceptsTotal lymphocyte countCD4 cell countAntiretroviral therapyCell countLymphocyte countHuman immunodeficiency virus (HIV) diseaseOpportunistic infection prophylaxisPotential surrogate markerResource-limited settingsHIV diseaseInfection prophylaxisLaboratory markersOpportunistic infectionsSurrogate markerDisease progressionClinical utilityImmune functionTherapeutic interventionsTherapyKey laboratory measurementsMonitoring responseVirus diseaseLack of availabilityDiseaseCount
2002
A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298)
Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298). AIDS Research And Human Retroviruses 2002, 18: 699-704. PMID: 12167276, DOI: 10.1089/088922202760072311.Peer-Reviewed Original ResearchConceptsCD4 cell countStandard of careD4TViral loadWeek 12Copies/Cell countMedian baseline viral loadPhase II Randomized StudyD4T armDual nucleoside therapyAntiretroviral-naive patientsBaseline viral loadWeeks of monotherapyViral load reductionTreatment of patientsDevelopment of multidrugAntiretroviral-NaiveAntiviral suppressionNaive patientsCD4 cellsImmunologic effectsHIV infectionRandomized studyNucleoside therapy
2000
In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy
Havlir D, Tierney C, Friedland G, Pollard R, Smeaton L, Sommadossi J, Fox L, Kessler H, Fife K, Richman D. In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy. The Journal Of Infectious Diseases 2000, 182: 321-325. PMID: 10882616, DOI: 10.1086/315683.Peer-Reviewed Original ResearchConceptsCD4 cell countD4TCell countD4T armD4T monotherapyWeeks of therapyHuman immunodeficiency virusCopies/mLGreater antiviral activityT monotherapyHIV RNACurrent regimenImmunodeficiency virusPharmacologic antagonismCombination therapyMean reductionZidovudineAntiviral activityVivo antagonismProgressive declinePatientsCells/DdIIntracellular levelsTherapy
1999
Efficacy and Safety of Delavirdine Mesylate With Zidovudine and Didanosine Compared With Two-Drug Combinations of These Agents in Persons With HIV Disease With CD4 Counts of 100 to 500 cells/mm3 (ACTG 261)
Friedland G, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M. Efficacy and Safety of Delavirdine Mesylate With Zidovudine and Didanosine Compared With Two-Drug Combinations of These Agents in Persons With HIV Disease With CD4 Counts of 100 to 500 cells/mm3 (ACTG 261). JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 21: 281-292. PMID: 10428106, DOI: 10.1097/00126334-199908010-00005.Peer-Reviewed Original ResearchConceptsCells/mm3CD4 cell countTwo-drug combinationsCell countHIV-1 RNA changesHIV-1 RNA levelsMonths of monotherapyThree-drug regimenTwo-drug armTwo-drug regimensGastrointestinal side effectsThree-drug combinationDelavirdine mesylateNon-nucleoside reverseCD4 countCD4 cellsHIV diseaseKey efficacyMulticenter trialCopies/Antiretroviral activityHIV-1Side effectsDidanosineZidovudine